Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.34 |
| ▸ | PNMT | P11086 | 2/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29122626 | 0.86 | HTR2A (0.39) | ADRA2APNMTADRA2BADRA2CHTR2A | |
| SCHEMBL29448023 | 0.79 | USP2 (0.42) | HTR2AHTR2CALDH1A1SRD5A1HTR2B | |
| SCHEMBL28740984 | 0.79 | USP2 (0.42) | HTR2AHTR2CALDH1A1SRD5A1HTR2B | |
| SCHEMBL30701801 | 0.79 | KDM1A (0.44) | KDM1AADRA2APNMTADRA2BADRA2C | |
| SCHEMBL27029648 | 0.79 | KDM1A (0.44) | KDM1AADRA2APNMTADRA2BADRA2C | |
| SCHEMBL31490277 | 0.79 | KDM1A (0.44) | KDM1AADRA2APNMTADRA2BADRA2C | |
| SCHEMBL31490434 | 0.79 | KDM1A (0.44) | KDM1AADRA2APNMTADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL23362561 | 0.77 | KDM1A (0.46) | KDM1AADRA2APNMTADRA2BADRA2C | |
| SCHEMBL28740986 | 0.76 | LMNA (0.43) | HTR2AHTR2C | |
| SCHEMBL28882981 | 0.76 | KDM1A (0.35) | KDM1ACAMK2AADRA2APNMTADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919335-B2 | Administering a therapeutically effective amount of a heterocyclic compound to the patient for the treatment of inosine monophosphate dehydrogenase associated disorders, such as allograft rejection | BRISTOL-MYERS SQUIBB CO. (US) | 2005-07-19 | — | — | US | disclosed |
| US-20020040022-A1 | Heterocycles that are inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY | 2002-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040022-A1 | Heterocycles that are inhibitors of IMPDH enzyme | XDH, IMPDH1, IMPDH2 | KDM1A 2546/4885CAMK2A 4773/4885ADRA2A 2660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.